Eptinezumab Anti-CGRP monoclonal antibody Treatment of migraine

被引：0

作者：

Lu, Lingyun ^{[1
]}

Liu, Meijun ^{[2
]}

Hu, Songshan ^{[1
]}

Liu, Yao ^{[3
]}

Yang, Dongdong ^{[2
]}

Hong, Peiwei ^{[4
]}

机构：

[1] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[2] Chengdu Univ Tradit Chinese Med, Affiliated Hosp 1, Chengdu, Sichuan, Peoples R China

[3] Xindu Hosp Tradit Chinese Med, Chengdu, Sichuan, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China

来源：

DRUGS OF THE FUTURE | 2017年 / 42卷 / 10期

关键词：

Eptinezumab; ALD-403; Anti-CGRP; Antimigraine drugs; GENE-RELATED PEPTIDE; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR ANTAGONIST; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; TELCAGEPANT; EFFICACY; SAFETY; TOLERABILITY;

D O I：

10.1358/dof.2017.042.10.2701433

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Eptinezumab (ALD-403) is a genetically engineered, humanized, desialylated anti-calcitonin gene-related peptide (CGRP) IgG1 monoclonal antibody that selectively binds to both a and beta forms of human CGRP, which is a promising therapeutic target for migraine. Pharmacokinetic data indicated that monthly dosing of an intravenous eptinezumab infusion could maintain bioactive levels and blood concentration for a long time. Phase I and II studies evaluating the safety and efficacy of eptinezumab in episodic and chronic migraine were completed with encouraging results, and there are currently three large phase III studies ongoing. This review summarizes the clinical trials already conducted or ongoing and the initial findings regarding the safety and efficacy of eptinezumab for the treatment of migraine.

引用

页码：609 / 615

页数：7

共 50 条

[11] Late Response to Anti-CGRP Monoclonal Antibodies in Migraine
Barbanti, Piero
Aurilia, Cinzia
Egeo, Gabriella
Torelli, Paola
Proietti, Stefania
Cevoli, Sabina
Bonassi, Stefano
NEUROLOGY, 2023, 101 (11) : 482 - 488
[12] Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies
Khodavirdi, Ani C.
Multani, Jasjit K.
Oh, Sam S.
Vuvu, Fiston
Bensink, Mark E.
Stockl, Karen M.
Hawkins, Kevin
Chiang, Chia-Chun
Green, A. Laine
Tepper, Stewart J.
FRONTIERS IN NEUROLOGY, 2024, 15
[13] Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine
Van der Arend, Britt W. H.
Van Veelen, Nancy
De Ruijter, Joelle E. T.
Olsen, Michael H.
MaassenVanDenBrink, Antoinette
Terwindt, Gisela M.
FRONTIERS IN NEUROLOGY, 2024, 15
[14] Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Hugo Sevivas
Paula Fresco
European Journal of Medical Research, 27
[15] Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies
Negro, Andrea
Martelletti, Paolo
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (08) : 769 - 776
[16] Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Sevivas, Hugo
Fresco, Paula
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
[17] Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients
Schweiger, Vittorio
Bellamoli, Paola
Taus, Francesco
Gottin, Leonardo
Martini, Alvise
Nizzero, Marta
Bonora, Eleonora
Del Balzo, Giovanna
Donadello, Katia
Secchettin, Erica
Finco, Gabriele
De Santis, Daniele
Polati, Enrico
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (04)
[18] Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Amy R. Tso
Peter J. Goadsby
Current Treatment Options in Neurology, 2017, 19
[19] Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Tso, Amy R.
Goadsby, Peter J.
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2017, 19 (08)
[20] Randomized, Double-blind, Placebo-controlled Trial of ALD403 (eptinezumab), an Anti-CGRP Monoclonal Antibody for the Prevention of Chronic Migraine
Smith, J.
Dodick, D. W.
Goadsby, P. J.
Silberstein, S. D.
Lipton, R. B.
Hirman, J.
HEADACHE, 2017, 57 : 130 - 130

← 1 2 3 4 5 →